Evidence map›Paper›PMID 37446064›Full record

ReviewInternational journal of molecular sciences2023

Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?

Rita Tabanelli, Simone Brogi, Vincenzo Calderone

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Substance Addiction Rehabilitation Drugs.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rita TabanelliDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Simone BrogiDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.ORCID 0000-0001-9375-6242
Vincenzo CalderoneDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review article offers an outlook on the use of opioids as therapeutics for treating several diseases, including cancer and non-cancer pain, and focuses the analysis on the opportunity to target opioid receptors for treating opioid use disorder (OUD), drug withdrawal, and addiction. Unfortunately, as has been well established, the use of opioids presents a plethora of side effects, such as tolerance and physical and physiological dependence. Accordingly, considering the great pharmacological potential in targeting opioid receptors, the identification of opioid receptor ligands devoid of most of the adverse effects exhibited by current therapeutic agents is highly necessary. To this end, herein, we analyze some interesting molecules that could potentially be useful for treating OUD, with an in-depth analysis regarding in vivo studies and clinical trials.

Indexed as

Behavior, AddictiveDrug-Related Side Effects and Adverse ReactionsOpioid-Related DisordersSubstance Withdrawal SyndromeAnalgesics, OpioidHumansReceptors, OpioidAnalgesics, OpioidReceptors, Opioiddrug addictiondrug withdrawalopioid receptorsopioidsopioid use disorder (OUD)

Identifiers

PMID37446064
PMCPMC10341731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.